ISOMERIC PHARMACEUTICAL FORMULATION CONTAINING DFMO FOR THE TREATMENT OF CANCER

摘要

Preparations comprising a single enantiomer or defined non-racemic ratio of enantiomers of alpha-difluoromethylornithine (DFMO) are provided for treating, preventing, controlling the growth of and/or reducing the risk of cancers, tumors and other related neoplastic disorders. The preparations containing a substantially pure preparation of (-)-DFMO or a defined non-racemic ratio of DFMO enantiomers will provide an enhanced pharmacological activity relative to a preparation comprising racemic DFMO.